Gaudium IVF Board Approves Audited FY26 Standalone & Consolidated Financial Results
Gaudium IVF's Board approved audited standalone and consolidated results for FY26, ending March 31, 2026. Standalone profit before tax was ₹2,926.55 lakhs, while consolidated profit before tax was ₹3,219.56 lakhs. The company also announced a trading window closure until May 30, 2026.
The disclosure of audited financial results and the outcome of a board meeting are material information for investors. The confirmation of financial performance and the continuation of a trading window closure have a moderate impact on market participants.
The announcement reports financial results and board meeting outcomes, which are routine corporate disclosures. While the results are presented, there are no significant positive or negative surprises highlighted.
Gaudium IVF and Women Health Limited announced that its Board of Directors, in a meeting held on Thursday, May 28, 2026, approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The results were presented with an unmodified auditor’s report from S K G N & Associates LLP.
The Board meeting commenced at 4:00 p.m. IST and concluded at 6:45 p.m. IST. Concurrently, the company informed that the trading window for all designated persons and their immediate relatives will remain closed up to and including May 30, 2026, in accordance with the Gaudium’s Code on Prohibition of Insider Trading and SEBI regulations.
The financial statements reveal that for the year ended March 31, 2026, the standalone total income was ₹7,207.66 lakhs and the profit before tax was ₹2,926.55 lakhs. For the same period, consolidated total income stood at ₹10,488.82 lakhs with a profit before tax of ₹3,219.56 lakhs.
During the year, Gaudium IVF also completed its Initial Public Offer (IPO) of 20,886,200 equity shares, listed on NSE and BSE on February 27, 2026. The IPO raised ₹9,000.08 lakhs through a fresh issue and ₹7,500.02 lakhs from a selling shareholder.
What to do with a filing like this
Gaudium IVF and Women Health Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gaudium IVF and Women Health Limited. Read the original for the full detail.